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Background: This study aimed to compare the therapeutic outcomes and fatal carotid blow out syndrome (CBOS)
incidence rates between two different stereotactic body radiotherapy (SBRT) protocols.
Methods: The study included 75 patients with inoperable locally recurrent head and neck cancer treated with SBRT
in our department between June 2007 and March 2011. The first 43 patients were treated sequentially (group I).
Then our SBRT protocol was changed due to the high rate of CBOS, and the following 32 patients were treated
every other day in a prospective institutional protocol (group II).
Results: Median overall survival in group I and group II was 11 months and 23 months, respectively (P = 0.006). We
observed 11 cases of CBOS. Only 1 of 7 patients (14%) with CBOS survived in group I, whereas 2 of 4 patients (50%)
in group II remain alive. CBOS free median overall survivals were 9 months, and 23 months in group I and group II
respectively (P = 0.002). The median radiation dose received by the carotid artery in patients with CBOS was 36.5 Gy
(range: 34–42.8 Gy), versus 34.7 Gy (range: 0–44 Gy) in the patients that didn’t have CBOS (P = 0.15). CBOS did not
occur in any of the patients with a maximum carotid artery radiation dose <34 Gy.
Conclusions: Every other day SBRT protocol for re-irradiation of recurrent head and neck cancer is promising in
terms of decreasing the incidence of fatal CBOS.
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The rate of local recurrence or persistent disease in
patients with locally advanced head and neck cancer is
3%-50%, despite the use of multidisciplinary treatment
modalities [1-3]. Treatment choices for such patients are
sparse and outcomes are not satisfactory. The prognosis
is reported to be better in patients undergoing surgery,
which can be performed in only a minority of patients
[4-6]. Even when surgery is performed additional local
treatment is necessary because of the high rate of local
recurrence [4-8].
Re-irradiation is associated with an increase in local
control and overall survival. Three-dimensional con-
formal radiotherapy (3D-CRT) and intensity-modulated* Correspondence: gozyigit@hacettepe.edu.tr
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reproduction in any medium, provided the orradiotherapy (IMRT) series have reported local control
rates of 60%-70% for re-irradiation in patients with recur-
rent head and neck cancer; however, the occurrence of ser-
ious toxicity was high (10%-40%) [9-11]. Stereotactic body
radiotherapy (SBRT) is a relatively new technique for re-
irradiation of recurrent head and neck cancer. SBRT facili-
tates administration of high doses of radiation to the tumor
while offering maximal protection to adjacent organs. We
recently reported the results of SBRT in this group of pa-
tients [12]. Although our local control rate was higher than
that in IMRT series, the occurrence of carotid blowout syn-
drome (CBOS) was relatively high, and as such we subse-
quently altered our SBRT protocol. The present study
aimed to compare the local control rate, overall survival
rate, and toxicity rate of the 2 SBRT protocols (our previ-
ously reported and newer protocols) for re-irradiation in
patients with locally recurrent head and neck cancer.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient characteristics
Group 1 Group 2 P
Sex (n)
-Female 22 9 0.03
-Male 21 23
Age at SBRT (years)
-Minimum and maximum 19-87 15-83 >0.05
-Median 53 57
SBRT site (n)
-Nasopharynx 19 15 >0.05




Dose of primary radiation (Gy)
-Minimum and maximum 30-77.4 38-78 >0.05
-Median 65 64
Time between primary radiation
treatment and SBRT (months)
-Minimum and maximum 9-232 10-300 >0.05
-Median 35 36
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incidence changed after every other day SBRT schedule.
Methods
The study included 75 patients with inoperable recurrent
head and neck cancer that were treated with SBRT in our
department between June 2007 and March 2011. The first
43 patients were treated sequentially (group I), and then
our SBRT protocol was changed due to the high rate of
CBOS, so the following 32 patients were treated every
other day in a prospective institutional protocol (group II).
The study protocol was approved by the Hacettepe Uni-
versity Faculty of Medicine Institutional Review Board,
and written informed consent was obtained from all the
patients before undergoing re-irradiation. Distant metasta-
sis was ruled out based on bone scintigraphy, thoracic
computed tomography (CT), abdominal CT, or positron
emission tomography (PET) findings. All local instances
of recurrence were confirmed either radiologically or
histopathologically.
Patients were immobilized using a head and neck
thermoplastic mask. CT and magnetic resonance imaging
(MRI) (slice thickness: 1 mm) were performed with the
patients in the treatment position. The images obtained
were then fused for contouring. Gross tumor volume
(GTV) was delineated as the planning target volume
(PTV). Multiplan (Accuray Inc., Sunnyvale, CA) software
was used for inverse planning. The treatments were deliv-
ered via a CyberKnife (Accuray Inc., Sunnyvale, CA).
We previously reported that there was a significant
risk of CBOS in patients whose carotid arteries were
surrounded by the tumor >270° circumferentially [12];
therefore, we used CT angiography to follow-up this
particular subgroup of patients. All patients were in-
formed briefly about the importance of nasal bleeding
and were told to contact us immediately if they experi-
enced any bleeding-even minor bleeding. Patients were
followed-up monthly for the first 3 months post SBRT,
and then every 3 months for 2 years.
Overall survival, progression free survival, and survival
curves were computed using the Kaplan-Meier method
and compared by Cox-Mantel log-rank test. All statistical
analysis was performed using the SPSS 15.0 software.
Results
Patient characteristics are summarized in Table 1. Median
age of all the patients was 53 years (range: 15–87 years).
There wasn’t a significant difference in demographic or
clinical characteristics between the 2 groups. The most
common site of re-irradiation was the nasopharynx (n = 34
patients), followed by the oral cavity and larynx. The SBRT
treatment characteristics are given in Table 2. Median
overall survival was 14 months (range: 10.8-17.2 months)
for all patients. Median overall survival in group I andgroup II was 11 months and 23 months, respectively
(P = 0.006) (Figure 1). The overall survival rate in group
I and group II was 42% and 84% at 12 months, and 23%
and 38% at 24 months, respectively. Median CBOS free
overall survival was 9 months (range: 6.5-11 months) in
group I, and was 23 months (range: 10.8-38.1 months)
in group II (P = 0.002).
Complete response was achieved in 12 patients (16%),
17 patients (22.7%) had partial response, and stable dis-
ease was observed in 29 patients (38.7%). Ultimate local
control was achieved in 77.4% of the patients. The local
control rate was 67.5% in group I, versus 90.6% in group
II (P = 0.029). Progression-free survival was 13 months
for all patients, 9 months in group I, and 18 months in
group II (P = 0.004) (Figure 2). Tumor size was consid-
ered to be possible prognosticator. However, we could
not detect any significant difference in time to progres-
sion, overall survival, or risk of bleeding between the pa-
tients with GTV ≤52 versus GTV >52 mL.
The most common grade II and higher toxicities were
dysphagia (16%) and CBOS (14.7%). Dysphagia was ob-
served in 10 patients (23%) in group I, versus 3 patients
(6.3%) in group II (P = 0.047). In all, 7 patients (16%) in
group I had CBOS, but only 1 of them survived, whereas 4
patients (12.5%) in group II had CBOS and to date 2 re-
main alive. The median radiation dose received by the ca-
rotid artery in patients with CBOS was 36.5 Gy (range:
34–42.8 Gy), versus 34.7 Gy (range: 0–44 Gy) in the pa-
tients that didn’t have CBOS (P = 0.15). CBOS did not
Table 2 Treatment characteristics










Carotid artery dose (Gy)
-Range 2.5-42.5 6.8-39.1 >0.05
-Median 35 34.9
Temporomandibular joint dose (Gy)
- Range 0-42 0-33.5 0.217
-Median 24 14.7


















Figure 1 Overall survival analysis.
Figure 2 Progression-free survival.
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tery radiation dose <34 Gy. The treatment characteristics
of patients with CBOS are given in Table 3. The biologic
effective dose (BED) for late responding tissues assuming
an α/β ratio of 3 were calculated for the SBRT scheme and
for the cumulative dose received by the patient. The me-
dian BED of SBRT were 95 Gy3, and 92 Gy3 for patients
with and without CBOS respectively (p = 0.8). The cumu-
lative BED was 203 Gy3 in patients with CBOS whereas it
was 198 Gy3 in patients without CBOS (p = 0.7).
The circumference of the carotid artery entrapped by
the tumor was calculated in each patient; median carotidartery wall entrapment by the tumor in all patients was
180°, versus 270° in the patients that had bleeding were
considered. CBOS was not observed in patients with
lesions entrapping <180° of the carotid artery.
Discussion
Current study compared 2 SBRT protocols for re-
irradiation in locally recurrent head and neck cancer
patients in terms of therapeutic outcomes and toxicity. We
demonstrated that a simple strategy change in fractionation














1 I 157 Hypopharynx 60 30/5 41.8 Complete response
2 I 173 Retromolar trigone 60 35/5 59 Progression
3 I 130 Larynx 60 30/5 39.4 Complete response
4 I 29 Nasopharynx 70 35/5 46.6 Partial response
5 I 101 Nasopharynx 66 30/5 38.5 Complete response
6 I 37 Nasopharynx 65 30/5 37.5 Progression
7 I 50 Nasopharynx 66 32/5 40.7 Stabile
8 II 55 Nasopharynx 66 32/6 46 Partial response
9 II 127 Larynx 70 30/5 37.5 Stabile
10 II 30 Hypopharynx 64 30/5 41 Stabile
11 II 51 Oral cavity 70 30/5 38.5 Stabile
GTV: gross tumor volume, Gy: gray, fx: fraction, SBRT: strereotactic body radiotherapy, I: consecutive day, II: every other day.
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other serious SBRT related toxicities. The 2-year overall
survival rate in every other day protocol is among the best
to be reported in the literature.
With conformal radiotherapy or IMRT modalities ra-
diation doses of 60 Gy resulted in response rates of 60%-
70% in patients with recurrent head and neck cancer;
however, the occurrence of grade 3 or higher serious late
effects was also high (40%) [10,11,13]. There is a growing
body of evidence for re-irradiation of head and neck
cancer patients with SBRT protocols. George et al.
reported a 26% local control rate and 22% overall sur-
vival rate without grade 4 or higher side effects in re-
sponse to doses of 20–30 Gy administered in 5 fractions
[14]. Another study that included 36 patients with recur-
rent head and neck cancer that were re-irradiated with a
median dose of 30 Gy in 3–5 fractions reported that the
1-year local control rate was 61%, but that grade 3 or
higher side effects occurred in 37% of patients3. In an
earlier study we compared 3D-CRT and SBRT in 51 re-
current nasopharyngeal cancer patients; the 2-year local
control rate was similar in both groups (80% versus
82%), but serious late effects were significantly less com-
mon in the SBRT group (48% versus 21%, P < 0.05) [15].
Furthermore we noticed that fatal CBOS rates were
much higher than the previously reported reirradiation
series [16-18]. Since we used very high dose per fraction
in a previously irradiated patient the interval between
two consecutive fractions might be inadequate in terms
of sublethal damage repair in critical tissues. In the light
of this hypothetical idea, which is also supported by the
study of King et al. as they showed that every other day
protocol resulted in a reduced rectal toxicity rate in
prostate cancer patients treated with SBRT, we decided
to change our SBRT fractionation schedule by increasing
the interval between fractions [19]. Consequently weobserved that group II fared better than sequential
group in terms of toxicities, particularly in terms of fatal
CBOS. In a recent article Yamazaki et al. concluded that
the every other day treatment may have a potential im-
pact on adverse toxicities as most papers reporting
CBOS used SBRT in consequtive days [20]. Our results
supports the idea by Yamazaki et al., but in contrast to
the literature we observed CBOS also in every other
day treatment group [21,22].
The current BED formula has not been validated for
the large doses per fraction however it is used to evalu-
ate different schemas in terms of adverse reactions. We
calculated the BED for late responding tissues in order
to reach a cut off value for the CBOS. However, we
couldn’t find a specific cut-off point for the carotid ar-
tery cumulative dose.
It may be argued that the median follow up time for
every other day protocol was inadequate to asses CBOS.
However, it is noteworthy that all cases of CBOS were
observed in the first year of SBRT in group I, and mini-
mum follow up was longer than 1 year with a median
follow up of 23 months in group II. It seems that the de-
crease in fatal CBOS incidince resulted in an increase in
OS rates of patients in group II.
We previously reported that tumor surrounding >180°
of the carotid artery are associated with a significantly ele-
vated risk of bleeding in stereotactic re-irradiation of
recurrent head and neck cancer. In current study we
performed further analysis on the relationship between
the carotid artery radiation dose and the risk of bleeding.
We noticed that all patients with bleeding had a median
carotid artery radiation dose above 34 Gy. Likewise, none
of the patients with a tumor surrounding <180° of the ca-
rotid artery experienced bleeding. Therefore clinicians
should be aware of dose limits of carotid arteries to pre-
vent that fatal complication.
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In the absence of a prospective randomized trial, our
current institutional SBRT protocol for re-irradiation of lo-
cally recurrent head and neck cancer is to treat patients
every other day. If an individual SBRT plan violates the
limits of the carotid artery dose mentioned above or the
tumor entraps the carotid artery more than 180°, we rec-
ommend IMRT with conventional fractionation. However,
further prospective trials are required to clarify both the
role of SBRT and the optimal fractionation regimen in lo-
cally recurrent head and neck cancers.
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